Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.

Tirzepatide, a dual glucose-dependent insulinotropic peptide/GLP-1 receptor agonist (GIP/GLP-1RA), significantly improved glycemic control and reduced body weight in patients with T2DM.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.

This exploratory analysis from DAPA-HF showed that dapagliflozin, compared to placebo, reduced new-onset T2DM in patients with HFrEF without diabetes at baseline.

The STEP 1 trial demonstrated a 15.3 kg weight loss and a sustained ≥5% reduction in body weight in 86.4% of participants after 68 weeks in individuals with overweight or obesity who were treated with semaglutide once-weekly.

John McMurray and Milton Packer proposed a new algorithm to achieve treatment with a beta-blocker, SGLT2i, ARNI and MRA within 4 weeks in patients with HFrEF.

This study investigated the relative risk of more than 50 clinical risk factors and biomarkers with incident CHD in 4 age groups in women.

The EMPA-TROPISM trial demonstrated that 6 months treatment of empagliflozin improved LV structure and function, as well as functional capacity and quality of life in nondiabetic patients with HFrEF.

A risk score based on elevated levels of hs-cTnT, NT-proBNP, and hs-CRP, and presence of left ventricular hypertrophy can stratify incident HF risk in patients with dysglycemia without CVD.

A subanalysis of EMPEROR-Reduced demonstrated that sacubitril/valsartan treatment in patients with HFrEF did not affect risk reducing effects of empagliflozin on HF and kidney events.

The 2021 update to the 2017 heart failure ECDP was just published. Prof. Januzzi explains the contribution of this document in addition to the guidelines and shares the most important updates.